

# Global Selective Cardiac Myosin Inhibitors Market Growth 2026-2032

<https://marketpublishers.com/r/GE9722770517EN.html>

Date: May 2026

Pages: 81

Price: US\$ 3,660.00 (Single User License)

ID: GE9722770517EN

## Abstracts

The global Selective Cardiac Myosin Inhibitors market size is predicted to grow from US\$ 815 million in 2025 to US\$ 1770 million in 2032; it is expected to grow at a CAGR of 12.0% from 2026 to 2032.

In 2025, global Selective Cardiac Myosin Inhibitors production reached approximately 107.49K Units, with an average global market price of around 7749 USD per Unit.

Selective Cardiac Myosin Inhibitors are a class of targeted therapies—typically small molecules—that directly bind to cardiac (?-) myosin in heart muscle and reduce the number and/or force of actin–myosin cross-bridges formed during contraction. By dampening excessive contractility and lowering myocardial energy use, they can decrease hypercontractility and obstruction and improve filling dynamics, and are most prominently used (or developed) for hypertrophic cardiomyopathy (especially obstructive HCM) and related hypercontractile cardiac conditions.

Selective Cardiac Myosin Inhibitors are gaining momentum because they directly address a long-standing gap in hypertrophic cardiomyopathy and other hypercontractile conditions: for many patients, traditional care has centered on symptom management or invasive procedures rather than precisely dialing down the excessive contractile force that drives obstruction, impaired filling, and day-to-day limitation. By selectively modulating cardiac myosin—the core molecular engine of contraction—these therapies offer a mechanism-based way to reduce hypercontractility and improve cardiac dynamics without permanently altering heart anatomy, while their titratable nature supports a more individualized balance between symptom relief and preservation of systolic function.

Selective Cardiac Myosin Inhibitors primarily source upstream raw materials including basic chemical raw materials such as nitrogen-containing heterocyclic compounds and chiral amines, key intermediates, and excipients. Typical raw material suppliers include Merck, Bio-Techne, InvivoChem, and Enamine.

The single-line production capacity of Selective Cardiac Myosin Inhibitors varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

United States market for Selective Cardiac Myosin Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Selective Cardiac Myosin Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Selective Cardiac Myosin Inhibitors is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Selective Cardiac Myosin Inhibitors players cover BMS, Cytokinetics, Braveheart Bio, Jiangsu Hengrui Medicine, China Medical System, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Selective Cardiac Myosin Inhibitors Industry Forecast" looks at past sales and reviews total world Selective Cardiac Myosin Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Selective Cardiac Myosin Inhibitors sales for 2026 through 2032. With Selective Cardiac Myosin Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Selective Cardiac Myosin Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Selective Cardiac Myosin Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Selective Cardiac Myosin Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Selective Cardiac Myosin Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Selective Cardiac Myosin Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Selective Cardiac Myosin Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Selective Cardiac Myosin Inhibitors market by product type, application, key manufacturers and key regions and countries.

#### Segmentation by Type:

?-Cardiac Myosin Inhibitors

?-Cardiac Myosin Inhibitors

#### Segmentation by Chemical Form:

Small Molecules

Peptides

Others

#### Segmentation by Action Mechanism:

Allosteric Inhibition

ATPase Direct Inhibition

#### Segmentation by Application:

Hypertrophic Cardiomyopathy (HCM)

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

BMS

Cytokinetics

Braveheart Bio

Jiangsu Hengrui Medicine

China Medical System

Key Questions Addressed in this Report

What is the 10-year outlook for the global Selective Cardiac Myosin Inhibitors market?

What factors are driving Selective Cardiac Myosin Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Selective Cardiac Myosin Inhibitors market opportunities vary by end market size?

How does Selective Cardiac Myosin Inhibitors break out by Type, by Application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Selective Cardiac Myosin Inhibitors Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Selective Cardiac Myosin Inhibitors by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Selective Cardiac Myosin Inhibitors by Country/Region, 2021, 2025 & 2032

#### 2.2 Selective Cardiac Myosin Inhibitors Segment by Type

- 2.2.1  $\beta$ -Cardiac Myosin Inhibitors
- 2.2.2  $\alpha$ -Cardiac Myosin Inhibitors
- 2.2.3 Selective Cardiac Myosin Inhibitors Sales by Type
  - 2.2.3.1 Global Selective Cardiac Myosin Inhibitors Sales Market Share by Type (2021-2026)
  - 2.2.3.2 Global Selective Cardiac Myosin Inhibitors Revenue and Market Share by Type (2021-2026)
  - 2.2.3.3 Global Selective Cardiac Myosin Inhibitors Sale Price by Type (2021-2026)

#### 2.3 Selective Cardiac Myosin Inhibitors Segment by Chemical Form

- 2.3.1 Small Molecules
- 2.3.2 Peptides
- 2.3.3 Others
- 2.3.4 Selective Cardiac Myosin Inhibitors Sales by Chemical Form
  - 2.3.4.1 Global Selective Cardiac Myosin Inhibitors Sales Market Share by Chemical Form (2021-2026)
  - 2.3.4.2 Global Selective Cardiac Myosin Inhibitors Revenue and Market Share by Chemical Form (2021-2026)

2.3.4.3 Global Selective Cardiac Myosin Inhibitors Sale Price by Chemical Form (2021-2026)

2.4 Selective Cardiac Myosin Inhibitors Segment by Action Mechanism

2.4.1 Allosteric Inhibition

2.4.2 ATPase Direct Inhibition

2.4.3 Selective Cardiac Myosin Inhibitors Sales by Action Mechanism

2.4.3.1 Global Selective Cardiac Myosin Inhibitors Sales Market Share by Action Mechanism (2021-2026)

2.4.3.2 Global Selective Cardiac Myosin Inhibitors Revenue and Market Share by Action Mechanism (2021-2026)

2.4.3.3 Global Selective Cardiac Myosin Inhibitors Sale Price by Action Mechanism (2021-2026)

2.5 Selective Cardiac Myosin Inhibitors Segment by Application

2.5.1 Hypertrophic Cardiomyopathy (HCM)

2.5.2 Others

2.5.3 Selective Cardiac Myosin Inhibitors Sales by Application

2.5.3.1 Global Selective Cardiac Myosin Inhibitors Sale Market Share by Application (2021-2026)

2.5.3.2 Global Selective Cardiac Myosin Inhibitors Revenue and Market Share by Application (2021-2026)

2.5.3.3 Global Selective Cardiac Myosin Inhibitors Sale Price by Application (2021-2026)

### **3 GLOBAL BY COMPANY**

3.1 Global Selective Cardiac Myosin Inhibitors Breakdown Data by Company

3.1.1 Global Selective Cardiac Myosin Inhibitors Annual Sales by Company (2021-2026)

3.1.2 Global Selective Cardiac Myosin Inhibitors Sales Market Share by Company (2021-2026)

3.2 Global Selective Cardiac Myosin Inhibitors Annual Revenue by Company (2021-2026)

3.2.1 Global Selective Cardiac Myosin Inhibitors Revenue by Company (2021-2026)

3.2.2 Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Company (2021-2026)

3.3 Global Selective Cardiac Myosin Inhibitors Sale Price by Company

3.4 Key Manufacturers Selective Cardiac Myosin Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Selective Cardiac Myosin Inhibitors Product Location

## Distribution

3.4.2 Players Selective Cardiac Myosin Inhibitors Products Offered

## 3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

## 3.6 New Products and Potential Entrants

## 3.7 Market M&A Activity & Strategy

# **4 WORLD HISTORIC REVIEW FOR SELECTIVE CARDIAC MYOSIN INHIBITORS BY GEOGRAPHIC REGION**

## 4.1 World Historic Selective Cardiac Myosin Inhibitors Market Size by Geographic Region (2021-2026)

4.1.1 Global Selective Cardiac Myosin Inhibitors Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Selective Cardiac Myosin Inhibitors Annual Revenue by Geographic Region (2021-2026)

## 4.2 World Historic Selective Cardiac Myosin Inhibitors Market Size by Country/Region (2021-2026)

4.2.1 Global Selective Cardiac Myosin Inhibitors Annual Sales by Country/Region (2021-2026)

4.2.2 Global Selective Cardiac Myosin Inhibitors Annual Revenue by Country/Region (2021-2026)

## 4.3 Americas Selective Cardiac Myosin Inhibitors Sales Growth

## 4.4 APAC Selective Cardiac Myosin Inhibitors Sales Growth

## 4.5 Europe Selective Cardiac Myosin Inhibitors Sales Growth

## 4.6 Middle East & Africa Selective Cardiac Myosin Inhibitors Sales Growth

# **5 AMERICAS**

## 5.1 Americas Selective Cardiac Myosin Inhibitors Sales by Country

5.1.1 Americas Selective Cardiac Myosin Inhibitors Sales by Country (2021-2026)

5.1.2 Americas Selective Cardiac Myosin Inhibitors Revenue by Country (2021-2026)

## 5.2 Americas Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026)

## 5.3 Americas Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026)

## 5.4 United States

## 5.5 Canada

## 5.6 Mexico

## 5.7 Brazil

## **6 APAC**

### 6.1 APAC Selective Cardiac Myosin Inhibitors Sales by Region

6.1.1 APAC Selective Cardiac Myosin Inhibitors Sales by Region (2021-2026)

6.1.2 APAC Selective Cardiac Myosin Inhibitors Revenue by Region (2021-2026)

### 6.2 APAC Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026)

### 6.3 APAC Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026)

#### 6.4 China

#### 6.5 Japan

#### 6.6 South Korea

#### 6.7 Southeast Asia

#### 6.8 India

#### 6.9 Australia

#### 6.10 China Taiwan

## **7 EUROPE**

### 7.1 Europe Selective Cardiac Myosin Inhibitors by Country

7.1.1 Europe Selective Cardiac Myosin Inhibitors Sales by Country (2021-2026)

7.1.2 Europe Selective Cardiac Myosin Inhibitors Revenue by Country (2021-2026)

### 7.2 Europe Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026)

### 7.3 Europe Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026)

#### 7.4 Germany

#### 7.5 France

#### 7.6 UK

#### 7.7 Italy

#### 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

### 8.1 Middle East & Africa Selective Cardiac Myosin Inhibitors by Country

8.1.1 Middle East & Africa Selective Cardiac Myosin Inhibitors Sales by Country (2021-2026)

8.1.2 Middle East & Africa Selective Cardiac Myosin Inhibitors Revenue by Country (2021-2026)

### 8.2 Middle East & Africa Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026)

8.3 Middle East & Africa Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026)

- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Selective Cardiac Myosin Inhibitors
- 10.3 Manufacturing Process Analysis of Selective Cardiac Myosin Inhibitors
- 10.4 Industry Chain Structure of Selective Cardiac Myosin Inhibitors

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

- 11.1 Sales Channel
  - 11.1.1 Direct Channels
  - 11.1.2 Indirect Channels
- 11.2 Selective Cardiac Myosin Inhibitors Distributors
- 11.3 Selective Cardiac Myosin Inhibitors Customer

## **12 WORLD FORECAST REVIEW FOR SELECTIVE CARDIAC MYOSIN INHIBITORS BY GEOGRAPHIC REGION**

- 12.1 Global Selective Cardiac Myosin Inhibitors Market Size Forecast by Region
  - 12.1.1 Global Selective Cardiac Myosin Inhibitors Forecast by Region (2027-2032)
  - 12.1.2 Global Selective Cardiac Myosin Inhibitors Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Selective Cardiac Myosin Inhibitors Forecast by Type (2027-2032)

## 12.7 Global Selective Cardiac Myosin Inhibitors Forecast by Application (2027-2032)

### 13 KEY PLAYERS ANALYSIS

#### 13.1 BMS

13.1.1 BMS Company Information

13.1.2 BMS Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

13.1.3 BMS Selective Cardiac Myosin Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 BMS Main Business Overview

13.1.5 BMS Latest Developments

#### 13.2 Cytokinetics

13.2.1 Cytokinetics Company Information

13.2.2 Cytokinetics Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

13.2.3 Cytokinetics Selective Cardiac Myosin Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Cytokinetics Main Business Overview

13.2.5 Cytokinetics Latest Developments

#### 13.3 Braveheart Bio

13.3.1 Braveheart Bio Company Information

13.3.2 Braveheart Bio Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

13.3.3 Braveheart Bio Selective Cardiac Myosin Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Braveheart Bio Main Business Overview

13.3.5 Braveheart Bio Latest Developments

#### 13.4 Jiangsu Hengrui Medicine

13.4.1 Jiangsu Hengrui Medicine Company Information

13.4.2 Jiangsu Hengrui Medicine Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

13.4.3 Jiangsu Hengrui Medicine Selective Cardiac Myosin Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Jiangsu Hengrui Medicine Main Business Overview

13.4.5 Jiangsu Hengrui Medicine Latest Developments

#### 13.5 China Medical System

13.5.1 China Medical System Company Information

13.5.2 China Medical System Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

13.5.3 China Medical System Selective Cardiac Myosin Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 China Medical System Main Business Overview

13.5.5 China Medical System Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Selective Cardiac Myosin Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Selective Cardiac Myosin Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of  $\beta$ -Cardiac Myosin Inhibitors

Table 4. Major Players of  $\beta$ -Cardiac Myosin Inhibitors

Table 5. Global Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026) & (K Units)

Table 6. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Type (2021-2026)

Table 7. Global Selective Cardiac Myosin Inhibitors Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Type (2021-2026)

Table 9. Global Selective Cardiac Myosin Inhibitors Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Major Players of Small Molecules

Table 11. Major Players of Peptides

Table 12. Major Players of Others

Table 13. Global Selective Cardiac Myosin Inhibitors Sales by Chemical Form (2021-2026) & (K Units)

Table 14. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Chemical Form (2021-2026)

Table 15. Global Selective Cardiac Myosin Inhibitors Revenue by Chemical Form (2021-2026) & (\$ million)

Table 16. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Chemical Form (2021-2026)

Table 17. Global Selective Cardiac Myosin Inhibitors Sale Price by Chemical Form (2021-2026) & (US\$/Unit)

Table 18. Major Players of Allosteric Inhibition

Table 19. Major Players of ATPase Direct Inhibition

Table 20. Global Selective Cardiac Myosin Inhibitors Sales by Action Mechanism (2021-2026) & (K Units)

Table 21. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Action Mechanism (2021-2026)

Table 22. Global Selective Cardiac Myosin Inhibitors Revenue by Action Mechanism (2021-2026) & (\$ million)

Table 23. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Action Mechanism (2021-2026)

Table 24. Global Selective Cardiac Myosin Inhibitors Sale Price by Action Mechanism (2021-2026) & (US\$/Unit)

Table 25. Global Selective Cardiac Myosin Inhibitors Sale by Application (2021-2026) & (K Units)

Table 26. Global Selective Cardiac Myosin Inhibitors Sale Market Share by Application (2021-2026)

Table 27. Global Selective Cardiac Myosin Inhibitors Revenue by Application (2021-2026) & (\$ million)

Table 28. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Application (2021-2026)

Table 29. Global Selective Cardiac Myosin Inhibitors Sale Price by Application (2021-2026) & (US\$/Unit)

Table 30. Global Selective Cardiac Myosin Inhibitors Sales by Company (2021-2026) & (K Units)

Table 31. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Company (2021-2026)

Table 32. Global Selective Cardiac Myosin Inhibitors Revenue by Company (2021-2026) & (\$ millions)

Table 33. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Company (2021-2026)

Table 34. Global Selective Cardiac Myosin Inhibitors Sale Price by Company (2021-2026) & (US\$/Unit)

Table 35. Key Manufacturers Selective Cardiac Myosin Inhibitors Producing Area Distribution and Sales Area

Table 36. Players Selective Cardiac Myosin Inhibitors Products Offered

Table 37. Selective Cardiac Myosin Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 38. New Products and Potential Entrants

Table 39. Market M&A Activity & Strategy

Table 40. Global Selective Cardiac Myosin Inhibitors Sales by Geographic Region (2021-2026) & (K Units)

Table 41. Global Selective Cardiac Myosin Inhibitors Sales Market Share Geographic Region (2021-2026)

Table 42. Global Selective Cardiac Myosin Inhibitors Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 43. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Geographic Region (2021-2026)

Table 44. Global Selective Cardiac Myosin Inhibitors Sales by Country/Region (2021-2026) & (K Units)

Table 45. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Country/Region (2021-2026)

Table 46. Global Selective Cardiac Myosin Inhibitors Revenue by Country/Region (2021-2026) & (\$ millions)

Table 47. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Country/Region (2021-2026)

Table 48. Americas Selective Cardiac Myosin Inhibitors Sales by Country (2021-2026) & (K Units)

Table 49. Americas Selective Cardiac Myosin Inhibitors Sales Market Share by Country (2021-2026)

Table 50. Americas Selective Cardiac Myosin Inhibitors Revenue by Country (2021-2026) & (\$ millions)

Table 51. Americas Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026) & (K Units)

Table 52. Americas Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026) & (K Units)

Table 53. APAC Selective Cardiac Myosin Inhibitors Sales by Region (2021-2026) & (K Units)

Table 54. APAC Selective Cardiac Myosin Inhibitors Sales Market Share by Region (2021-2026)

Table 55. APAC Selective Cardiac Myosin Inhibitors Revenue by Region (2021-2026) & (\$ millions)

Table 56. APAC Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026) & (K Units)

Table 57. APAC Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026) & (K Units)

Table 58. Europe Selective Cardiac Myosin Inhibitors Sales by Country (2021-2026) & (K Units)

Table 59. Europe Selective Cardiac Myosin Inhibitors Revenue by Country (2021-2026) & (\$ millions)

Table 60. Europe Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026) & (K Units)

Table 61. Europe Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026) & (K Units)

Table 62. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales by Country

(2021-2026) & (K Units)

Table 63. Middle East & Africa Selective Cardiac Myosin Inhibitors Revenue Market Share by Country (2021-2026)

Table 64. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales by Type (2021-2026) & (K Units)

Table 65. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales by Application (2021-2026) & (K Units)

Table 66. Key Market Drivers & Growth Opportunities of Selective Cardiac Myosin Inhibitors

Table 67. Key Market Challenges & Risks of Selective Cardiac Myosin Inhibitors

Table 68. Key Industry Trends of Selective Cardiac Myosin Inhibitors

Table 69. Selective Cardiac Myosin Inhibitors Raw Material

Table 70. Key Suppliers of Raw Materials

Table 71. Selective Cardiac Myosin Inhibitors Distributors List

Table 72. Selective Cardiac Myosin Inhibitors Customer List

Table 73. Global Selective Cardiac Myosin Inhibitors Sales Forecast by Region (2027-2032) & (K Units)

Table 74. Global Selective Cardiac Myosin Inhibitors Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 75. Americas Selective Cardiac Myosin Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 76. Americas Selective Cardiac Myosin Inhibitors Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 77. APAC Selective Cardiac Myosin Inhibitors Sales Forecast by Region (2027-2032) & (K Units)

Table 78. APAC Selective Cardiac Myosin Inhibitors Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 79. Europe Selective Cardiac Myosin Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 80. Europe Selective Cardiac Myosin Inhibitors Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 81. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales Forecast by Country (2027-2032) & (K Units)

Table 82. Middle East & Africa Selective Cardiac Myosin Inhibitors Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 83. Global Selective Cardiac Myosin Inhibitors Sales Forecast by Type (2027-2032) & (K Units)

Table 84. Global Selective Cardiac Myosin Inhibitors Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 85. Global Selective Cardiac Myosin Inhibitors Sales Forecast by Application (2027-2032) & (K Units)

Table 86. Global Selective Cardiac Myosin Inhibitors Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 87. BMS Basic Information, Selective Cardiac Myosin Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 88. BMS Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

Table 89. BMS Selective Cardiac Myosin Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. BMS Main Business

Table 91. BMS Latest Developments

Table 92. Cytokinetics Basic Information, Selective Cardiac Myosin Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 93. Cytokinetics Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

Table 94. Cytokinetics Selective Cardiac Myosin Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Cytokinetics Main Business

Table 96. Cytokinetics Latest Developments

Table 97. Braveheart Bio Basic Information, Selective Cardiac Myosin Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 98. Braveheart Bio Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

Table 99. Braveheart Bio Selective Cardiac Myosin Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. Braveheart Bio Main Business

Table 101. Braveheart Bio Latest Developments

Table 102. Jiangsu Hengrui Medicine Basic Information, Selective Cardiac Myosin Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 103. Jiangsu Hengrui Medicine Selective Cardiac Myosin Inhibitors Product Portfolios and Specifications

Table 104. Jiangsu Hengrui Medicine Selective Cardiac Myosin Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. Jiangsu Hengrui Medicine Main Business

Table 106. Jiangsu Hengrui Medicine Latest Developments

Table 107. China Medical System Basic Information, Selective Cardiac Myosin Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 108. China Medical System Selective Cardiac Myosin Inhibitors Product Portfolios

and Specifications

Table 109. China Medical System Selective Cardiac Myosin Inhibitors Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 110. China Medical System Main Business

Table 111. China Medical System Latest Developments

## List Of Figures

### LIST OF FIGURES

Figure 1. Picture of Selective Cardiac Myosin Inhibitors

Figure 2. Selective Cardiac Myosin Inhibitors Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Selective Cardiac Myosin Inhibitors Sales Growth Rate 2021-2032 (K Units)

Figure 7. Global Selective Cardiac Myosin Inhibitors Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. Selective Cardiac Myosin Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. Selective Cardiac Myosin Inhibitors Sales Market Share by Country/Region (2025)

Figure 10. Selective Cardiac Myosin Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of  $\beta$ -Cardiac Myosin Inhibitors

Figure 12. Product Picture of  $\alpha$ -Cardiac Myosin Inhibitors

Figure 13. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Type in 2026

Figure 14. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Type (2021-2026)

Figure 15. Product Picture of Small Molecules

Figure 16. Product Picture of Peptides

Figure 17. Product Picture of Others

Figure 18. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Chemical Form in 2026

Figure 19. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Chemical Form (2021-2026)

Figure 20. Product Picture of Allosteric Inhibition

Figure 21. Product Picture of ATPase Direct Inhibition

Figure 22. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Action Mechanism in 2026

Figure 23. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Action Mechanism (2021-2026)

Figure 24. Selective Cardiac Myosin Inhibitors Consumed in Hypertrophic

## Cardiomyopathy (HCM)

Figure 25. Global Selective Cardiac Myosin Inhibitors Market: Hypertrophic Cardiomyopathy (HCM) (2021-2026) & (K Units)

Figure 26. Selective Cardiac Myosin Inhibitors Consumed in Others

Figure 27. Global Selective Cardiac Myosin Inhibitors Market: Others (2021-2026) & (K Units)

Figure 28. Global Selective Cardiac Myosin Inhibitors Sale Market Share by Application (2025)

Figure 29. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Application in 2025

Figure 30. Selective Cardiac Myosin Inhibitors Sales by Company in 2025 (K Units)

Figure 31. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Company in 2025

Figure 32. Selective Cardiac Myosin Inhibitors Revenue by Company in 2025 (\$ millions)

Figure 33. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Company in 2025

Figure 34. Global Selective Cardiac Myosin Inhibitors Sales Market Share by Geographic Region (2021-2026)

Figure 35. Global Selective Cardiac Myosin Inhibitors Revenue Market Share by Geographic Region in 2025

Figure 36. Americas Selective Cardiac Myosin Inhibitors Sales 2021-2026 (K Units)

Figure 37. Americas Selective Cardiac Myosin Inhibitors Revenue 2021-2026 (\$ millions)

Figure 38. APAC Selective Cardiac Myosin Inhibitors Sales 2021-2026 (K Units)

Figure 39. APAC Selective Cardiac Myosin Inhibitors Revenue 2021-2026 (\$ millions)

Figure 40. Europe Selective Cardiac Myosin Inhibitors Sales 2021-2026 (K Units)

Figure 41. Europe Selective Cardiac Myosin Inhibitors Revenue 2021-2026 (\$ millions)

Figure 42. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales 2021-2026 (K Units)

Figure 43. Middle East & Africa Selective Cardiac Myosin Inhibitors Revenue 2021-2026 (\$ millions)

Figure 44. Americas Selective Cardiac Myosin Inhibitors Sales Market Share by Country in 2025

Figure 45. Americas Selective Cardiac Myosin Inhibitors Revenue Market Share by Country (2021-2026)

Figure 46. Americas Selective Cardiac Myosin Inhibitors Sales Market Share by Type (2021-2026)

Figure 47. Americas Selective Cardiac Myosin Inhibitors Sales Market Share by

Application (2021-2026)

Figure 48. United States Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 49. Canada Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 50. Mexico Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 51. Brazil Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 52. APAC Selective Cardiac Myosin Inhibitors Sales Market Share by Region in 2025

Figure 53. APAC Selective Cardiac Myosin Inhibitors Revenue Market Share by Region (2021-2026)

Figure 54. APAC Selective Cardiac Myosin Inhibitors Sales Market Share by Type (2021-2026)

Figure 55. APAC Selective Cardiac Myosin Inhibitors Sales Market Share by Application (2021-2026)

Figure 56. China Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 57. Japan Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 58. South Korea Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 59. Southeast Asia Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 60. India Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 61. Australia Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 62. China Taiwan Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 63. Europe Selective Cardiac Myosin Inhibitors Sales Market Share by Country in 2025

Figure 64. Europe Selective Cardiac Myosin Inhibitors Revenue Market Share by Country (2021-2026)

Figure 65. Europe Selective Cardiac Myosin Inhibitors Sales Market Share by Type (2021-2026)

Figure 66. Europe Selective Cardiac Myosin Inhibitors Sales Market Share by Application (2021-2026)

Figure 67. Germany Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 68. France Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 69. UK Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 70. Italy Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 71. Russia Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 72. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales Market Share by Country (2021-2026)

Figure 73. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales Market Share by Type (2021-2026)

Figure 74. Middle East & Africa Selective Cardiac Myosin Inhibitors Sales Market Share by Application (2021-2026)

Figure 75. Egypt Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 76. South Africa Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 77. Israel Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 78. Turkey Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 79. GCC Countries Selective Cardiac Myosin Inhibitors Revenue Growth 2021-2026 (\$ millions)

Figure 80. Manufacturing Cost Structure Analysis of Selective Cardiac Myosin Inhibitors in 2026

Figure 81. Manufacturing Process Analysis of Selective Cardiac Myosin Inhibitors

Figure 82. Industry Chain Structure of Selective Cardiac Myosin Inhibitors

Figure 83. Channels of Distribution

Figure 84. Global Selective Cardiac Myosin Inhibitors Sales Market Forecast by Region (2027-2032)

Figure 85. Global Selective Cardiac Myosin Inhibitors Revenue Market Share Forecast by Region (2027-2032)

Figure 86. Global Selective Cardiac Myosin Inhibitors Sales Market Share Forecast by Type (2027-2032)

Figure 87. Global Selective Cardiac Myosin Inhibitors Revenue Market Share Forecast by Type (2027-2032)

Figure 88. Global Selective Cardiac Myosin Inhibitors Sales Market Share Forecast by Application (2027-2032)

Figure 89. Global Selective Cardiac Myosin Inhibitors Revenue Market Share Forecast by Application (2027-2032)

## I would like to order

Product name: Global Selective Cardiac Myosin Inhibitors Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GE9722770517EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE9722770517EN.html>